Literature DB >> 23609359

Analysis of differentially expressed genes in ductal carcinoma with DNA microarray.

B-H Zhang1, J Liu, Q-X Zhou, D Zuo, Y Wang.   

Abstract

AIM: The aim of this study is to investigate the dysregulated biological functions that play important role in the occurrence and development of breast invasive ductal carcinoma (IDC).
MATERIALS AND METHODS: We downloaded the gene expression profile data from gene expression omnibus (GEO) database, including 42 disease samples and 143 adjacent histological normal samples. Significance analysis of microarrays (SAM) was employed to identify differentially expressed genes (DEGs) between the normal and disease samples. Gene ontology (GO) function enrichment analysis was based on Software DAVID, followed by KEGG pathway enrichment analysis. TRANSFAC database and HPRD database were employed to construct the transcriptional regulatory network (Tnet) and protein-protein interaction (PPI) network, respectively.
RESULTS: We got a total of 1769 genes significantly differentially expressed, including 907 up-regulated genes and 862 down-regulated genes. Functional analysis revealed that hormone-responsive genes are related with the occurrence of cancer. Then, we successfully constructed IDC-specific Tnet and PPI network with DEGs response to hormone and obtained some hub genes, such as FOS and PIK3R1, in these networks. Besides, ten modules were found in these networks.
CONCLUSIONS: Hormone-responsive genes and modules may play an important role in the occurrence and development of IDC. Based on the findings above, we got a preliminary understand of the occurrence, development and metastasis of the IDC and possibly provided effective information on the biogenesis of IDC.

Entities:  

Mesh:

Year:  2013        PMID: 23609359

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

1.  A systems biological approach reveals multiple crosstalk mechanism between gram-positive and negative bacterial infections: an insight into core mechanism and unique molecular signatures.

Authors:  R Muthukumar; V Alexandar; Berla Thangam; Shiek S S J Ahmed
Journal:  PLoS One       Date:  2014-02-28       Impact factor: 3.240

2.  Somatic loss of PIK3R1 may sensitize breast cancer to inhibitors of the MAPK pathway.

Authors:  Sanja B Turturro; Matthew S Najor; Timothy Yung; Liam Portt; Christopher S Malarkey; Abde M Abukhdeir; Melody A Cobleigh
Journal:  Breast Cancer Res Treat       Date:  2019-06-17       Impact factor: 4.872

3.  Genome-wide ChIP-seq analysis of TCF4 binding regions in colorectal cancer cells.

Authors:  Chen Chen; Yachun Lu; Jie Liu; Lisha Li; Na Zhao; Biaoyang Lin
Journal:  Int J Clin Exp Med       Date:  2014-11-15

4.  Profiling of alternative polyadenylation sites in luminal B breast cancer using the SAPAS method.

Authors:  Xinmei Wang; Mingyue Li; Yingchun Yin; Liang Li; Yuqian Tao; Dengguo Chen; Jianzhao Li; Hongmei Han; Zhenbo Hou; Baohua Zhang; Xinyun Wang; Yu Ding; Haiyan Cui; Hengming Zhang
Journal:  Int J Mol Med       Date:  2014-10-20       Impact factor: 4.101

5.  Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1.

Authors:  Xiaoping Pan; Xiaolv Hong; Jinguo Lai; Lu Cheng; Yandong Cheng; Mingmei Yao; Rong Wang; Na Hu
Journal:  Front Oncol       Date:  2020-04-30       Impact factor: 6.244

6.  Integrating genomics and proteomics data to predict drug effects using binary linear programming.

Authors:  Zhiwei Ji; Jing Su; Chenglin Liu; Hongyan Wang; Deshuang Huang; Xiaobo Zhou
Journal:  PLoS One       Date:  2014-07-18       Impact factor: 3.240

7.  Identifying Network Perturbation in Cancer.

Authors:  Maxim Grechkin; Benjamin A Logsdon; Andrew J Gentles; Su-In Lee
Journal:  PLoS Comput Biol       Date:  2016-05-04       Impact factor: 4.475

Review 8.  Wnt-signalling pathways and microRNAs network in carcinogenesis: experimental and bioinformatics approaches.

Authors:  Emenike K Onyido; Eloise Sweeney; Abdolrahman Shams Nateri
Journal:  Mol Cancer       Date:  2016-09-02       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.